HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice

• Published in: World journal of gastroenterology : WJG Vol. 22; no. 26; pp. 5879 - 5887
• Main Authors: Grillo, Federica, Fassan, Matteo, Sarocchi, Francesca, Fiocca, Roberto, Mastracci, Luca
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 14.07.2016
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - metabolism; Adenocarcinoma - pathology; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor - metabolism; Biopsy; cancer;HER2;Heterogeneity;Immunohistochemistry;FISH; Carcinogenesis; Esophagogastric Junction; Gastric; Humans; Immunohistochemistry; In Situ Hybridization; In Situ Hybridization, Fluorescence; Patient Selection; Receptor, ErbB-2 - metabolism; Stomach Neoplasms - drug therapy; Stomach Neoplasms - metabolism; Stomach Neoplasms - pathology; Topic Highlight; Trastuzumab - therapeutic use; Immunohistochemistry; FISH; Heterogeneity; HER2; Gastric cancer
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v22.i26.5879

HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. In these types of cancer, accurate assessment of HER2 status is mandatory, for selecting patients who may benefit from targeted therapies with anti-HER2 drugs such as Trastuzumab. This manuscript focuses on HER2 in gastric carcinogenesis, on optimal evaluation of HER2 and on the possible causes which may contribute to inaccurate HER2 evaluation. Similarly to breast cancer HER2 evaluation, standardization of HER2 testing in gastric cancer is necessary in diagnostic practice. The three principle aspects which require consideration are:(1) the choice of sample with regards to cancer morphology- intestinal vs diffuse areas;(2) the choice of scoring criteria- use of HER2 scoring criteria specific for gastric cancer; and(3) the choice of HER2 evaluation methods- use of an algorithm in which both immunohistochemistry and in situ hybridization play a role. Problematic issues include:(1) pre-analytic variables with particular emphasis on fixation;(2) recommended methodology for HER2 assessment(immunohistochemistry vs in situ hybridization);(3) HER2 heterogeneity both within the primary tumor and between primary tumor and metastases;(4) reliability of biopsies in HER 2 evaluation; and(5) quantity of sample(FFPE blocks from surgical specimens or endoscopic biopsies) necessary for an adequate assessment.